The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Novartis
Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC).
 
Ann-Lii Cheng
Consulting or Advisory Role - Daiichi Sankyo; Eisai; Exelixis
 
Sumitra Thongprasert
No Relationships to Disclose
 
Ho Yeong Lim
No Relationships to Disclose
 
Wattana Sukeepaisarnjaroen
No Relationships to Disclose
 
Tsai-Sheng Yang
No Relationships to Disclose
 
Cheng-Chung Wu
No Relationships to Disclose
 
Yee Chao
No Relationships to Disclose
 
Stephen Lam Chan
No Relationships to Disclose
 
Masatoshi Kudo
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Bayer; Novartis
 
Yoon-Koo Kang
Honoraria - Bayer; Novartis
Consulting or Advisory Role - Bayer; Novartis
Research Funding - Bayer; Novartis
 
Hongming Pan
No Relationships to Disclose
 
Kazushi Numata
No Relationships to Disclose
 
Guohong Han
No Relationships to Disclose
 
Binaifer Balsara
No Relationships to Disclose
 
Yong Zhang
Employment - Novartis
 
Ana-Maria Rodriguez
Employment - Novartis
 
Yi Zhang
Employment - Novartis
 
Yongyu Wang
Employment - Novartis
 
Ronnie Tung-Ping Poon
No Relationships to Disclose